Combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6)

Kiyoshi Yoshino,Shoji Kamiura,Takeshi Yokoi,Ruriko Nakae,Masami Fujita,Masahiko Takemura,Kazushige Adachi,Akinori Wakimoto,Takamichi Nishizaki,Yasuhiko Shiki,Tateki Tsutsui,Yuki Kanda,Eiji Kobayashi,Kae Hashimoto,Seiji Mabuchi,Yutaka Ueda,Kenjiro Sawada,Takuji Tomimatsu,Tadashi Kimura

Combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6)

2017

Kiyoshi Yoshino
Shoji Kamiura
Takeshi Yokoi
Ruriko Nakae
Masami Fujita
Masahiko Takemura
Kazushige Adachi
Akinori Wakimoto
Takamichi Nishizaki
Yasuhiko Shiki
Tateki Tsutsui
Yuki Kanda
Eiji Kobayashi
Kae Hashimoto
Seiji Mabuchi
Yutaka Ueda
Kenjiro Sawada
Takuji Tomimatsu
Tadashi Kimura

Purpose To develop a new therapeutic strategy for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancers, we evaluated the feasibility and efficacy of irinotecan and gemcitabine combination chemotherapy.

Keywords:

Refractory
Taxane
Peritoneal cancer
Recurrent Ovarian Cancer
Oncology
Gemcitabine
Medicine
Chemotherapy
Internal medicine
Irinotecan
Peritoneal Neoplasm
Deoxycytidine
combination chemotherapy
Camptothecin

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations